Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a GLP-1 Receptor Agonist: A Multinational Cohort Study

Manel Pladevall-Vila; Ryan Ziemiecki; Catherine B. Johannes; Anam M. Khan; Daniel Mines; Natalie Ebert; Csaba P. Kovesdy; Reimar W. Thomsen; Brenda N. Baak; Aníbal García-Sempere; Hiroshi Kanegae; Craig I. Coleman; Michael Walsh; Ina Trolle Andersen; Clara Rodríguez Bernal; Celia Robles Cabaniñas; Christian Fynbo Christiansen; Alfredo E. Farjat; Alain Gay; Patrick Gee; Ron M.C. Herings; Isabel Hurtado; Naoki Kashihara; Frederik Pagh Bredahl Kristensen; Fangfang Liu; Suguru Okami; Jetty A. Overbeek; Fernie J.A.Penning van Beest; Satoshi Yamashita; Yuichiro Yano; J. Bradley Layton; David Vizcaya; Nikolaus G. Oberprieler

doi:10.1007/s13300-025-01717-8

Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a GLP-1 Receptor Agonist: A Multinational Cohort Study

Manel Pladevall-Vila, Ryan Ziemiecki, Catherine B. Johannes, Anam M. Khan, Daniel Mines, Natalie Ebert, Csaba P. Kovesdy, Reimar W. Thomsen, Brenda N. Baak, Aníbal García-Sempere, Hiroshi Kanegae, Craig I. Coleman, Michael Walsh, Ina Trolle Andersen, Clara Rodríguez Bernal, Celia Robles Cabaniñas, Christian Fynbo Christiansen, Alfredo E. Farjat, Alain Gay, Patrick GeeRon M.C. Herings, Isabel Hurtado, Naoki Kashihara, Frederik Pagh Bredahl Kristensen, Fangfang Liu, Suguru Okami, Jetty A. Overbeek, Fernie J.A.Penning van Beest, Satoshi Yamashita, Yuichiro Yano, J. Bradley Layton, David Vizcaya, Nikolaus G. Oberprieler^*

^*Corresponding author for this work

Department of Clinical Medicine - Department of Clinical Epidemiology

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

Abstract

Introduction: Novel therapies are emerging for the prevention of chronic kidney disease (CKD) progression in patients with type 2 diabetes (T2D). Within the FOUNTAIN platform (NCT05526157; EUPAS48148), this real-world study aimed to characterize cohorts of adults with CKD and T2D starting therapy with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) in Europe, Japan, and the United States (US) during 2012–2021. Methods: This multinational, multicohort study was conducted in five data sources: the Danish National Health Registers (DNHR) (Denmark), PHARMO Data Network (PHARMO) (The Netherlands), Valencia Health System Integrated Database (VID) (Spain), Japan Chronic Kidney Disease Database Extension (J-CKD-DB-Ex) (Japan), and Optum’s de-identified Clinformatics® Data Mart Database (CDM) (US). Eligible patients had T2D (defined by data source-specific algorithms) and CKD (based on diagnosis codes, estimated glomerular filtration rate values, and/or urine albumin-to-creatinine ratio) and initiated an GLP-1 RA during 2012–2021. Baseline demographic, lifestyle, and clinical characteristics were analyzed, and treatment patterns were described. Results: Study cohorts included 18,929 GLP-1 RA initiators in DNHR; 476 in PHARMO; 11,798 in VID; 329 in J-CKD-DB-Ex; and 70,158 in CDM. Across cohorts, mean age ranged from 66.1 years in J-CKD-DB-Ex to 67.9 years in CDM, and between 46.6% (PHARMO) and 59.6% (J-CKD-DB-Ex) of patients were men. There was a steady increase in GLP-1 RA initiators from 2012 (when 1.6–4.8% of GLP-1 RA initiators started therapy) to 2019 (when 19.8–31.5% started therapy). The median duration of initial treatment with a GLP-1 RA ranged from 2.3 months (PHARMO) to 12.4 months (VID). At 1-year follow-up, between 52% (CDM) and 78% (DNHR) of patients were receiving treatment. Findings suggested that GLP-1 RA use was independent of CKD severity. Conclusions: During 2012–2021, GLP-1 RA use steadily increased across multinational cohorts of patients with T2D and CKD, and persistence with treatment was high. GLP-1 use was independent of CKD severity.

Original language	English
Article number	100502
Journal	Diabetes therapy
Volume	16
Pages (from-to)	931-954
ISSN	1869-6953
DOIs	https://doi.org/10.1007/s13300-025-01717-8
Publication status	Published - 2025

Keywords

Chronic
Chronic kidney disease
Diabetes mellitus
Drug utilization
FOUNTAIN platform
Glucagon-like peptide-1 receptor agonists
Renal insufficiency
Type 2

Access to Document

10.1007/s13300-025-01717-8Licence: CC BY-NC

Library access?

Check availability with the Royal Danish Library

Cite this

Pladevall-Vila, M., Ziemiecki, R., Johannes, C. B., Khan, A. M., Mines, D., Ebert, N., Kovesdy, C. P., Thomsen, R. W., Baak, B. N., García-Sempere, A., Kanegae, H., Coleman, C. I., Walsh, M., Andersen, I. T., Bernal, C. R., Cabaniñas, C. R., Christiansen, C. F., Farjat, A. E., Gay, A., ... Oberprieler, N. G. (2025). Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a GLP-1 Receptor Agonist: A Multinational Cohort Study. Diabetes therapy, 16, 931-954. Article 100502. https://doi.org/10.1007/s13300-025-01717-8

@article{cec62052c186490387528d1a279ee2b6,

title = "Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a GLP-1 Receptor Agonist: A Multinational Cohort Study",

abstract = "Introduction: Novel therapies are emerging for the prevention of chronic kidney disease (CKD) progression in patients with type 2 diabetes (T2D). Within the FOUNTAIN platform (NCT05526157; EUPAS48148), this real-world study aimed to characterize cohorts of adults with CKD and T2D starting therapy with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) in Europe, Japan, and the United States (US) during 2012–2021. Methods: This multinational, multicohort study was conducted in five data sources: the Danish National Health Registers (DNHR) (Denmark), PHARMO Data Network (PHARMO) (The Netherlands), Valencia Health System Integrated Database (VID) (Spain), Japan Chronic Kidney Disease Database Extension (J-CKD-DB-Ex) (Japan), and Optum{\textquoteright}s de-identified Clinformatics{\textregistered} Data Mart Database (CDM) (US). Eligible patients had T2D (defined by data source-specific algorithms) and CKD (based on diagnosis codes, estimated glomerular filtration rate values, and/or urine albumin-to-creatinine ratio) and initiated an GLP-1 RA during 2012–2021. Baseline demographic, lifestyle, and clinical characteristics were analyzed, and treatment patterns were described. Results: Study cohorts included 18,929 GLP-1 RA initiators in DNHR; 476 in PHARMO; 11,798 in VID; 329 in J-CKD-DB-Ex; and 70,158 in CDM. Across cohorts, mean age ranged from 66.1 years in J-CKD-DB-Ex to 67.9 years in CDM, and between 46.6% (PHARMO) and 59.6% (J-CKD-DB-Ex) of patients were men. There was a steady increase in GLP-1 RA initiators from 2012 (when 1.6–4.8% of GLP-1 RA initiators started therapy) to 2019 (when 19.8–31.5% started therapy). The median duration of initial treatment with a GLP-1 RA ranged from 2.3 months (PHARMO) to 12.4 months (VID). At 1-year follow-up, between 52% (CDM) and 78% (DNHR) of patients were receiving treatment. Findings suggested that GLP-1 RA use was independent of CKD severity. Conclusions: During 2012–2021, GLP-1 RA use steadily increased across multinational cohorts of patients with T2D and CKD, and persistence with treatment was high. GLP-1 use was independent of CKD severity.",

keywords = "Chronic, Chronic kidney disease, Diabetes mellitus, Drug utilization, FOUNTAIN platform, Glucagon-like peptide-1 receptor agonists, Renal insufficiency, Type 2",

author = "Manel Pladevall-Vila and Ryan Ziemiecki and Johannes, {Catherine B.} and Khan, {Anam M.} and Daniel Mines and Natalie Ebert and Kovesdy, {Csaba P.} and Thomsen, {Reimar W.} and Baak, {Brenda N.} and An{\'i}bal Garc{\'i}a-Sempere and Hiroshi Kanegae and Coleman, {Craig I.} and Michael Walsh and Andersen, {Ina Trolle} and Bernal, {Clara Rodr{\'i}guez} and Cabani{\~n}as, {Celia Robles} and Christiansen, {Christian Fynbo} and Farjat, {Alfredo E.} and Alain Gay and Patrick Gee and Herings, {Ron M.C.} and Isabel Hurtado and Naoki Kashihara and Kristensen, {Frederik Pagh Bredahl} and Fangfang Liu and Suguru Okami and Overbeek, {Jetty A.} and Beest, {Fernie J.A.Penning van} and Satoshi Yamashita and Yuichiro Yano and Layton, {J. Bradley} and David Vizcaya and Oberprieler, {Nikolaus G.}",

year = "2025",

doi = "10.1007/s13300-025-01717-8",

language = "English",

volume = "16",

pages = "931--954",

journal = "Diabetes therapy",

issn = "1869-6953",

publisher = "Springer Publishing Company",

}

Pladevall-Vila, M, Ziemiecki, R, Johannes, CB, Khan, AM, Mines, D, Ebert, N, Kovesdy, CP, Thomsen, RW, Baak, BN, García-Sempere, A, Kanegae, H, Coleman, CI, Walsh, M, Andersen, IT, Bernal, CR, Cabaniñas, CR, Christiansen, CF, Farjat, AE, Gay, A, Gee, P, Herings, RMC, Hurtado, I, Kashihara, N, Kristensen, FPB, Liu, F, Okami, S, Overbeek, JA, Beest, FJAPV, Yamashita, S, Yano, Y, Layton, JB, Vizcaya, D & Oberprieler, NG 2025, 'Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a GLP-1 Receptor Agonist: A Multinational Cohort Study', Diabetes therapy, vol. 16, 100502, pp. 931-954. https://doi.org/10.1007/s13300-025-01717-8

Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a GLP-1 Receptor Agonist: A Multinational Cohort Study. / Pladevall-Vila, Manel; Ziemiecki, Ryan; Johannes, Catherine B. et al.
In: Diabetes therapy, Vol. 16, 100502, 2025, p. 931-954.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

TY - JOUR

T1 - Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a GLP-1 Receptor Agonist

T2 - A Multinational Cohort Study

AU - Pladevall-Vila, Manel

AU - Ziemiecki, Ryan

AU - Johannes, Catherine B.

AU - Khan, Anam M.

AU - Mines, Daniel

AU - Ebert, Natalie

AU - Kovesdy, Csaba P.

AU - Thomsen, Reimar W.

AU - Baak, Brenda N.

AU - García-Sempere, Aníbal

AU - Kanegae, Hiroshi

AU - Coleman, Craig I.

AU - Walsh, Michael

AU - Andersen, Ina Trolle

AU - Bernal, Clara Rodríguez

AU - Cabaniñas, Celia Robles

AU - Christiansen, Christian Fynbo

AU - Farjat, Alfredo E.

AU - Gay, Alain

AU - Gee, Patrick

AU - Herings, Ron M.C.

AU - Hurtado, Isabel

AU - Kashihara, Naoki

AU - Kristensen, Frederik Pagh Bredahl

AU - Liu, Fangfang

AU - Okami, Suguru

AU - Overbeek, Jetty A.

AU - Beest, Fernie J.A.Penning van

AU - Yamashita, Satoshi

AU - Yano, Yuichiro

AU - Layton, J. Bradley

AU - Vizcaya, David

AU - Oberprieler, Nikolaus G.

PY - 2025

Y1 - 2025

N2 - Introduction: Novel therapies are emerging for the prevention of chronic kidney disease (CKD) progression in patients with type 2 diabetes (T2D). Within the FOUNTAIN platform (NCT05526157; EUPAS48148), this real-world study aimed to characterize cohorts of adults with CKD and T2D starting therapy with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) in Europe, Japan, and the United States (US) during 2012–2021. Methods: This multinational, multicohort study was conducted in five data sources: the Danish National Health Registers (DNHR) (Denmark), PHARMO Data Network (PHARMO) (The Netherlands), Valencia Health System Integrated Database (VID) (Spain), Japan Chronic Kidney Disease Database Extension (J-CKD-DB-Ex) (Japan), and Optum’s de-identified Clinformatics® Data Mart Database (CDM) (US). Eligible patients had T2D (defined by data source-specific algorithms) and CKD (based on diagnosis codes, estimated glomerular filtration rate values, and/or urine albumin-to-creatinine ratio) and initiated an GLP-1 RA during 2012–2021. Baseline demographic, lifestyle, and clinical characteristics were analyzed, and treatment patterns were described. Results: Study cohorts included 18,929 GLP-1 RA initiators in DNHR; 476 in PHARMO; 11,798 in VID; 329 in J-CKD-DB-Ex; and 70,158 in CDM. Across cohorts, mean age ranged from 66.1 years in J-CKD-DB-Ex to 67.9 years in CDM, and between 46.6% (PHARMO) and 59.6% (J-CKD-DB-Ex) of patients were men. There was a steady increase in GLP-1 RA initiators from 2012 (when 1.6–4.8% of GLP-1 RA initiators started therapy) to 2019 (when 19.8–31.5% started therapy). The median duration of initial treatment with a GLP-1 RA ranged from 2.3 months (PHARMO) to 12.4 months (VID). At 1-year follow-up, between 52% (CDM) and 78% (DNHR) of patients were receiving treatment. Findings suggested that GLP-1 RA use was independent of CKD severity. Conclusions: During 2012–2021, GLP-1 RA use steadily increased across multinational cohorts of patients with T2D and CKD, and persistence with treatment was high. GLP-1 use was independent of CKD severity.

AB - Introduction: Novel therapies are emerging for the prevention of chronic kidney disease (CKD) progression in patients with type 2 diabetes (T2D). Within the FOUNTAIN platform (NCT05526157; EUPAS48148), this real-world study aimed to characterize cohorts of adults with CKD and T2D starting therapy with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) in Europe, Japan, and the United States (US) during 2012–2021. Methods: This multinational, multicohort study was conducted in five data sources: the Danish National Health Registers (DNHR) (Denmark), PHARMO Data Network (PHARMO) (The Netherlands), Valencia Health System Integrated Database (VID) (Spain), Japan Chronic Kidney Disease Database Extension (J-CKD-DB-Ex) (Japan), and Optum’s de-identified Clinformatics® Data Mart Database (CDM) (US). Eligible patients had T2D (defined by data source-specific algorithms) and CKD (based on diagnosis codes, estimated glomerular filtration rate values, and/or urine albumin-to-creatinine ratio) and initiated an GLP-1 RA during 2012–2021. Baseline demographic, lifestyle, and clinical characteristics were analyzed, and treatment patterns were described. Results: Study cohorts included 18,929 GLP-1 RA initiators in DNHR; 476 in PHARMO; 11,798 in VID; 329 in J-CKD-DB-Ex; and 70,158 in CDM. Across cohorts, mean age ranged from 66.1 years in J-CKD-DB-Ex to 67.9 years in CDM, and between 46.6% (PHARMO) and 59.6% (J-CKD-DB-Ex) of patients were men. There was a steady increase in GLP-1 RA initiators from 2012 (when 1.6–4.8% of GLP-1 RA initiators started therapy) to 2019 (when 19.8–31.5% started therapy). The median duration of initial treatment with a GLP-1 RA ranged from 2.3 months (PHARMO) to 12.4 months (VID). At 1-year follow-up, between 52% (CDM) and 78% (DNHR) of patients were receiving treatment. Findings suggested that GLP-1 RA use was independent of CKD severity. Conclusions: During 2012–2021, GLP-1 RA use steadily increased across multinational cohorts of patients with T2D and CKD, and persistence with treatment was high. GLP-1 use was independent of CKD severity.

KW - Chronic

KW - Chronic kidney disease

KW - Diabetes mellitus

KW - Drug utilization

KW - FOUNTAIN platform

KW - Glucagon-like peptide-1 receptor agonists

KW - Renal insufficiency

KW - Type 2

UR - http://www.scopus.com/inward/record.url?scp=105000519252&partnerID=8YFLogxK

U2 - 10.1007/s13300-025-01717-8

DO - 10.1007/s13300-025-01717-8

M3 - Journal article

C2 - 40106222

AN - SCOPUS:105000519252

SN - 1869-6953

VL - 16

SP - 931

EP - 954

JO - Diabetes therapy

JF - Diabetes therapy

M1 - 100502

ER -

Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a GLP-1 Receptor Agonist: A Multinational Cohort Study

Abstract

Keywords

Access to Document

Library access?

Other files and links

Fingerprint

Cite this